SCL Lifesciences Limited

What SCL Lifesciences Limited does

SCL Lifesciences Limited is an India-headquartered, privately held pharmaceutical contract development and manufacturing organization (CDMO/CMO) founded in 1993 that produces active pharmaceutical ingredients (APIs), advanced intermediates, specialty chemicals, and mRNA vaccine ingredients for global pharmaceutical and biotechnology customers. The company operates two manufacturing sites near Chandigarh (Derabassi and Mohali/Bhagwanpura, Punjab) with combined capacity of 350KL, 9 cGMP-classified pharma blocks, and 82 reactors (1,000L-6,000L), plus a Greenfield third site, and an R&D-dedicated SCL Knowledge Centre at Genome Valley in Hyderabad. Its technology stack spans high-pressure, cryogenic, and high-temperature reactions, HPAPI manufacturing using an isolator facility, one of India's largest bromine-handling operations (3-3.5 MT/day), and mRNA platform chemistry including modified nucleotides, cap analogs, lipids, adjuvants, and phosphoramidites.

SCL generates revenue via B2B contracts across multiple streams: API supply (20+ commercial molecules including Atropine Sulfate, Pregabalin, Dexketoprofen Trometamol, Nitisinone, and Tiotropium Bromide), pharmaceutical intermediate sales (Carbapenem, Cephalosporin, Valsartan, Lisinopril, and other families), CDMO services spanning feasibility through commercial manufacturing and lifecycle management, mRNA vaccine ingredients, and specialty chemicals (contrast media, bromine derivatives, electronic chemicals). Pricing is negotiated project-by-project; there is no public list price. Sales is direct enterprise field sales with dedicated channels for international markets, Indian domestic, and vaccine ingredients. Approximately 80% of revenue is exported to 80+ countries across Europe, USA, Japan, Korea, Brazil, Turkey, Russia/CIS, MENA, and other regions.

The firm is differentiated by an unusually broad regulatory footprint — USFDA approvals (2015, 2017, 2018), PMDA Japan (2019), EDQM (2024), WHO Geneva (multiple cycles through 2019), MFDS Korea, and TGA Australia — and a 2013 joint venture with Mitsubishi Corporation, Japan that provided strategic capital and international reach. The customer base is diversified across regulated markets and segments (global generics and innovators, biotech/vaccine developers, specialty chemical niches) without disclosed anchor customer concentration. The firm is led by founder Chairman cum Management Director Parveen Goyal, with Director Udayan Sengupta driving international expansion and Director Saurav Goyal leading the New Product Development portfolio.

Name

SCL Lifesciences Limited

Legal name

SCL Lifesciences Ltd.

Website

https://scllifesciences.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

251–500 employees

Short description

SCL Lifesciences is an India-based pharmaceutical CDMO/CMO founded in 1993 that manufactures APIs, advanced intermediates, specialty chemicals, and mRNA vaccine ingredients for global pharmaceutical and biotech customers in regulated markets including Europe, USA, Japan, Korea, and MENA.

Ownership category

akta.pro rank

Product category

Pharmaceutical API Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ), CMC Regulatory Affairs (Modules 2/3, Variations, Post-Approval CMC) (HLAGAKAB), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Pharmaceutical API manufacturing
• Advanced intermediates supply
• CDMO contract services
• MRNA vaccine ingredients
• Specialty chemicals production

Headquarters

HQ city

Panchkula

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure

Revenue model

1. API Manufacturing & Sales: Manufacturing and sale of Active Pharmaceutical Ingredients (APIs) including commercial APIs (Atropine Sulfate, Carglumic Acid, Chlorzoxazone, Clopidogrel Besylate/Bisulfate, Dexketoprofen Trometamol, Diethyl Carbamazine Citrate, Febuxostat, Homatropine HBr/MBr, Ibandronate Sodium, Ipratropium Bromide, Ketoprofen, Ketorolac Tromethamine, Levofloxacin Hemihydrate, Nitisinone, Obidoxime HCl, Papaverine HCL, Pregabalin, Probenecid, Tiotropium Bromide, Vildagliptin) and APIs being launched (Bempedoic acid, Dapagliflozin, Daprodustat, Empagliflozin, Ketoprofen Lysinate, Ticagrelor, Tribenoside).
2. Pharmaceutical Intermediates Sales: Sale of advanced pharmaceutical intermediates including Carbapenem intermediates, Cephalosporin intermediates, Tiotropium intermediates, Valsartan intermediates, Lisinopril intermediates, Aripiprazole Lauroxil intermediates, Naftifine HCl intermediates, Epalrestat intermediates, Lorcaserin intermediate, Zopiclone intermediate, Eprosartan intermediate, Dapagliflozin intermediate, Dexketoprofen intermediate, Clopidogrel intermediate, Ticagrelor intermediate, Methotrexate intermediate, Empagliflozin intermediate, and specialty chemicals including contrast media, specialty bromine products, and electronic chemicals.
3. CDMO/Contract Manufacturing Services: Contract development and manufacturing services covering API drug substance development and manufacturing, custom synthesis, process development, analytical services, and technology transfer. Services span from feasibility studies through commercial manufacturing and regulatory stability studies. Timeline of 12-14 months for typical CDMO projects (3-6 months for lab validated products, 6 months for scale-up and validation).
4. mRNA Vaccine Ingredients: Manufacturing and supply of mRNA vaccine ingredients including nucleotides (N1-Methylpseudo-UTP, Pseudo-UTP, 5-Methyluridine Triphosphate, 5-Methylcytidine Triphosphate, UTP, ATP, GTP, CTP), precursors, DNA nucleotides, cap analogs, adjuvants, lipids, and phosphoramidites at R&D, commercial and GMP scales.
5. Specialty Chemicals: Specialty chemicals including contrast media, specialty bromine products, and electronic chemicals. Diverse specialty chemical projects undertaken for niche industries.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

SCL Lifesciences manufactures and supplies Active Pharmaceutical Ingredients (APIs), advanced pharmaceutical intermediates, specialty chemicals, and mRNA vaccine ingredients at commercial scale. The company operates as a CDMO/CMO providing end-to-end contract development, custom synthesis, process development, commercial manufacturing, and analytical services to pharmaceutical companies in regulated global markets, with ~80% of revenue from exports to Europe, USA, Japan, Korea, Brazil, MENA, and CIS countries.

Product overview

SCL Lifesciences operates as a CDMO/CMO offering a portfolio of pharma products and services. The core products include Active Pharmaceutical Ingredients (APIs) like Atropine Sulfate, Dexketoprofen Trometamol, and Pregabalin; Advanced Intermediates for Carbapenem, Cephalosporin, and Tiotropium synthesis; Specialty Chemicals (Contrast Media, Bromine Products); and mRNA Vaccine Ingredients (nucleotides, CAP analogs, lipids). The services are organized around API Drug Substance Development & Manufacturing, which encompasses Process Development, Commercial Manufacturing & Lifecycle Management, and Analytical Services. All new product development activities are undertaken at the SCL Knowledge Centre in Genome Valley, Hyderabad.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs) High-quality APIs including niche generics such as Atropine Sulfate, Dexketoprofen, Homatropine, and Pregabalin, serving therapeutic areas including NSAIDs, cardiovascular, anti-diabetic, anti-cholinergic, and CNS treatments for pharmaceutical formulators.
• Pharmaceutical Intermediates Advanced intermediates for pharmaceutical synthesis covering Carbapenem, Cephalosporin, Tiotropium, Valsartan, Lisinopril, Aripiprazole, Dapagliflozin, Empagliflozin, Methotrexate, and other therapeutic categories for pharma manufacturers.
• Specialty Chemicals Specialty chemicals including Contrast Media, Specialty Bromine Products, and Electronic Chemicals, leveraging one of the largest bromine handling facilities in India for large-scale manufacturing.
• mRNA Vaccine Ingredients Critical components for mRNA and DNA therapeutics including nucleotides (N1-Methylpseudo-UTP, Pseudo-UTP, 5-Methyluridine Triphosphate, 5-Methylcytidine Triphosphate), CAP analogs, adjuvants, lipids, and phosphoramidites supplied at R&D, commercial, and GMP scales.
• CDMO API Drug Substance Development & Manufacturing End-to-end contract API development and manufacturing services from route selection through commercialization, including CT stage development, high-potency molecules, and niche generics with global regulatory approvals for pharmaceutical clients.
• Analytical Services Advanced analytical testing including method development and validation, stability studies, raw material analysis, finished product testing, impurity profiling, and elemental impurities analysis compliant with ICH Q3D guidelines.

Quantifiable outcome

• ~80% export revenue from international markets (Europe, USA, Japan, Korea, Brazil, Turkey, Russia/CIS, MENA, South & Central America)
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature7 records

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Granules India: Indian pharmaceutical manufacturer focused on APIs, intermediates and finished dosages with multiple USFDA/EMA-approved sites exporting to regulated markets. Comparable in operating a backward-integrated API and intermediate model with global regulatory footprint.
• Sai Life Sciences: India-based CDMO providing contract development and manufacturing services for small-molecule APIs and intermediates to global pharma, with comparable regulatory-approved manufacturing sites. Direct competitor for innovator-pharma CDMO contracts in the same mid-tier Indian segment.
• Sequent Scientific: Indian API manufacturer with focus on niche generics, supported by a CDMO platform and multi-regulatory site approvals. Comparable in serving niche small-molecule API categories from India to regulated export markets including Europe, US and Japan.
• Alkyl Amines (India): Indian manufacturer of amines, fine chemicals and pharmaceutical intermediates for regulated markets. Comparable in operating a specialty chemicals and intermediates platform from India with backward integration and an export-heavy revenue mix.
• TriLink BioTechnologies: Specialist manufacturer of mRNA components including modified nucleotides, cap analogs and lipid reagents used by mRNA vaccine and therapeutic developers. Direct competitor to SCL's emerging mRNA vaccine ingredients pipeline at research, custom and GMP scales.

Broad incumbents

• Piramal Pharma Solutions: Global CDMO offering integrated API development and manufacturing services, including high-potency APIs, from sites across India, North America and Europe. Overlaps directly with SCL's HPAPI and small-molecule CDMO capabilities.
• Laurus Labs: Indian API and CDMO player offering APIs, intermediates and formulation services with strong regulatory filings across USFDA, WHO, and EDQM. Overlaps with SCL's small-molecule API and intermediate business, and competes for CDMO engagements in regulated markets.
• CMC Pharmaceuticals (CTIS / Cambrex): Global small-molecule API and CDMO business serving innovator pharma from sites in the US and Europe. Comparable as a buyer of custom synthesis and process development projects that SCL's CDMO service line also targets.
• Divis Laboratories: India-headquartered API and intermediates manufacturer with global regulatory approvals (USFDA, EDQM) serving similar innovator and generic pharma customers. Comparable in offering small-molecule APIs and intermediates with backward integration, but operates at significantly larger scale across multiple therapeutic categories.

Others

• Snowman Logistics (Snow Logistics / Deutsche Post DHL Cold Chain): Temperature-controlled logistics provider serving the Indian pharmaceutical industry. Adjacent ecosystem participant whose cold-chain capabilities support stable distribution of APIs, intermediates and biological materials relevant to SCL's export business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/scllifescienceslimited

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SCL Lifesciences Limited